Release time: 2018-07-09
On March 30, Shanghai Lungtin law firm and Fenglin Biomedical center held the innovative medicines market and generic drugs development forum to promote the development of China's medical industry. More than 40 medical R&D units and enterprises attended.
Dr. Xu Qinghong introduced the development of Hatch-Waxman Act and ANDA approval by FDA.She also introduced the infringement litidation procedure in US and analyzed the relevant laws and regulations in China for attendees better undersanding China and US juridical protection system and future of ANDA.
